Rhumbline Advisers Assembly Biosciences, Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.81 - $1.15 $1,945 - $2,762	2,402 New	2,402 $2,000
Q2 2021 Aug 05, 2021	SELL	$3.8 - $4.56 $163,829 - $196,595	-43,113 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$4.33 - $6.63 $12,080 - $18,497	-2,790 Reduced 6.08%	43,113 $198,000
Q4 2020 Feb 10, 2021	BUY	$4.87 - $17.29 $20,312 - $72,116	4,171 Added 9.99%	45,903 $278,000
Q3 2020 Nov 12, 2020	SELL	$15.08 - $27.04 $114,788 - $205,828	-7,612 Reduced 15.43%	41,732 $686,000

Q2 2020 Aug 13, 2020	BUY	$14.57 - $23.96 $72,879 - $119,847	5,002 Added 11.28%	49,344 $1.15 Million
Q1 2020 May 06, 2020	BUY	$10.27 - $21.23 $88,496 - $182,938	8,617 Added 24.12%	44,342 $658,000
Q4 2019 Feb 05, 2020	BUY	$8.36 - $23.81 $6,570 - $18,714	786 Added 2.25%	35,725 $731,000
Q3 2019 Oct 23, 2019	BUY	$9.83 - $14.82 $26,216 - $39,524	2,667 Added 8.26%	34,939 $343,000
Q2 2019 Aug 14, 2019	BUY	$12.9 - $20.8 $62,423 - $100,651	4,839 Added 17.64%	32,272 $435,000
Q1 2019 May 01, 2019	SELL	$17.7 - $24.93 $5,504 - $7,753	-311 Reduced 1.12%	27,433 $540,000
Q4 2018 Jan 31, 2019	BUY	$19.05 - $36.45 $182,918 - $349,992	9,602 Added 52.93%	27,744 $628,000
Q3 2018 Nov 07, 2018	BUY	$34.41 - $44.23 $54,952 - $70,635	1,597 Added 9.65%	18,142 $674,000
Q2 2018 Aug 06, 2018	BUY	$39.21 - $50.29 $55,678 - $71,411	1,420 Added 9.39%	16,545 $649,000
Q1 2018 May 02, 2018	BUY	$41.7 - $64.16 $95,451 - $146,862	2,289 Added 17.83%	15,125 $743,000
Q4 2017 Feb 09, 2018	SELL	$28.58 - $49.91 $60,132 - $105,010	-2,104 Reduced 14.08%	12,836 $581,000
Q3 2017 Nov 06, 2017	BUY	$23.08 - $34.92 $344,815 - $521,704	14,940	14,940 $522,000

Others Institutions Holding ASMB

# of Institutions

Shares Held

16.3K

Call Options Held

Put Options Held

ETF Managers Group, LLC Summit, NJ

16.3K
Shares

$223,841
0.0% of portfolio

View Full List

About ASSEMBLY BIOSCIENCES, INC.

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

More about ASMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account